9 New Drugs for Primary Care: Q3 2018

US Surgeon General: Add Cancer Warning to Alcoholic Beverage Labels

Slideshow

Which drugs are most important for your patients? Scroll through our quick slideshow to find out.

It's the end of the third quarter, which means Patient Care has scoured all of the newly FDA-approved drugs and found 9 we believe every primary care physician should know about. Find details in the slideshow below about the first generic version of the EpiPen, a first-in-class oral antibiotic acne treatment, and 7 other noteworthy drugs.

Related Content

Richard Payerchin

Primary Viewpoints: Immunizations with Dr Steven P. Furr

Murthy's advisory outlines evidence for the cancer-alcohol relationship and calls for greater efforts to increase public awareness of the risks from beer, wine, and spirits.

Keith A. Reynolds

October 1st 2024

Neumora Therapeutics Reports Disappointing Results from Phase 3 Study of Navacaprant in MDD

"Primary Viewpoints," a podcast from Patient Care Online, brings you an exclusive interview with Steven P. Furr, former president of the American Academy of Family Physicians.

Grace Halsey

Infectious Disease & Primary Care: A Conversation with IDWeek 2023 Chair

The failure of the novel kappa opioid receptor antagonist to best placebo in the first of triplicate phase 3 studies has Neumora concerned but not deterred.

October 25th 2023

Lexicon Receives Complete Response Letter for Sotagliflozin in Type 1 Diabetes and Chronic Kidney Disease

Listen to our latest podcast episode with Heather Yun, MD, for details on emerging pathogens, the role of primary care clinicians in the effort to rein in antimicrobial resistance, and more.

Denise Myshko

Higher Daily Step Count Linked to Lower Risk for Depression Among Adults

In November 2024, an FDA advisory committee said the benefits of sotagliflozin do not outweigh the risks in adults with type 1 diabetes and chronic kidney disease.

January 2nd 2025

US Surgeon General: Add Cancer Warning to Alcoholic Beverage Labels

Daily step counts of 5000 or more corresponded with fewer depressive symptoms, according to a recent systematic review and meta-analysis.

Related Content

Richard Payerchin

Primary Viewpoints: Immunizations with Dr Steven P. Furr

Murthy's advisory outlines evidence for the cancer-alcohol relationship and calls for greater efforts to increase public awareness of the risks from beer, wine, and spirits.

Keith A. Reynolds

October 1st 2024

Neumora Therapeutics Reports Disappointing Results from Phase 3 Study of Navacaprant in MDD

"Primary Viewpoints," a podcast from Patient Care Online, brings you an exclusive interview with Steven P. Furr, former president of the American Academy of Family Physicians.

Grace Halsey

Infectious Disease & Primary Care: A Conversation with IDWeek 2023 Chair

The failure of the novel kappa opioid receptor antagonist to best placebo in the first of triplicate phase 3 studies has Neumora concerned but not deterred.

October 25th 2023

Lexicon Receives Complete Response Letter for Sotagliflozin in Type 1 Diabetes and Chronic Kidney Disease

Listen to our latest podcast episode with Heather Yun, MD, for details on emerging pathogens, the role of primary care clinicians in the effort to rein in antimicrobial resistance, and more.

Denise Myshko

Higher Daily Step Count Linked to Lower Risk for Depression Among Adults

In November 2024, an FDA advisory committee said the benefits of sotagliflozin do not outweigh the risks in adults with type 1 diabetes and chronic kidney disease.

January 2nd 2025